

**CONTROLLED SUBSTANCES BOARD
MEETING
OCTOBER 2, 2002**

MEMBERS PRESENT: Cynthia Benning, R.Ph.; Roma Rowlands, Thomas Rudy, Ph.D.
and Robert W. Sloey

MEMBERS EXCUSED: Yvonne Bellay, DVM

STAFF PRESENT: Deanna Zychowski, Bureau Director, William Black, Legal
Counsel; Pamela Haack, Paralegal; Pamela Meicher, Program
Assistant

GUESTS: Mike Grafton, DEA-Milwaukee

CALL TO ORDER

The meeting was called to order by Cynthia Benning, Chair, at 9:31 a.m.

APPROVAL OF AGENDA

Amendments: Pharmacy Board – Monthly Drug Theft and Loss Report
DEA Handout - Temporary Placement of Benzylpiperazine and
Trifluoromethylphenylpiperazine into Schedule 1
William Black Handout – Ephedrine and Pseudoephedrine
Other Board Business – Kris Hendrickson - Forms

MOTION: Thomas Rudy moved, seconded by Roma Rowlands, to adopt the agenda
as amended. Motion carried unanimously.

SECRETARY OSCAR HERRERA

Secretary Oscar Herrera advised the Board that the base budget had been submitted for the
operating period July 1, 2003 through June 30, 2005.

Secretary Oscar Herrera discussed the Executive Board initiatives, some of which included
improved enforcement and better phone service, along with Division Administrator requests to
provide better service to the public.

Secretary Oscar Herrera announced that Dr. Ken Robbins will be the newly appointed
professional Psychiatrist member of the Controlled Substances Board.

APPROVAL OF MINUTES

Amendments: Page 3 first motion - Change motion; seconded by Roma Rowlands
Page 3 second motion – Add last name Bellay to Yvonne

MOTION: Thomas Rudy moved, seconded by Roma Rowley, to approve the minutes
of August 19, 2002, with amendments. Motion carried unanimously.

**REVIEW OF APPROVAL OF SCOPE STATEMENT TO CLASIFY CERTAIN
GAMMAHYDROXYBUTYRIC ACID (GHB) DRUG PRODUCTS IN
SCHEDULE III OF THE WISCONSIN CONTROLLED SUBSTANCES ACT
UNDER SECTIONS 961.11 AND 961.18**

William Black reviewed the scope statement with the Board.

MOTION: Robert Sloey moved, seconded by Thomas Rudy, to approve the scope statement for filing with the modification to add *FDA prescription* in front of drug product, in the SUBJECT statement. Motion carried unanimously.

**REVIEW OF MEMO RELATING TO MISSPELLING “FORMEBOLONE” IN
STATUTES**

The Board discussed the misspelling of Formebolone. The Board would like a letter sent to the reviser of the Statutes. William Black will request Pamela Haack write the letter to the reviser of statutes to correct the spelling.

MOTION: Thomas Rudy moved, seconded by Roma Rowlands, to make the correction to Formebolone by Bill Black forwarding a letter using the correct spelling for the Statutes. Motion carried unanimously.

SPECIAL USE AUTHORIZATION APPLICATIONS

The Board discussed and reviewed the SUA permit for USDA – ALPHIS Wildlife Services #748. After further discussion, the Board decided to forward the information to the Veterinary Examining Board and have them determine whether the activity described as non euthanasia amounts to unauthorized practice of veterinary medicine.

MOTION: Roma Rowlands moved, seconded by Robert Sloey, to request the Veterinary Examining Board review the application. Motion carried unanimously.

DRUG SUMMARY REPORTS

The Board discussed the Pharmacy Board – Monthly Drug Theft and Loss Report.

William Black led the discussion on the suggested Ohio Legislation for classifying psuedoephedrine as a controlled substance. The Board decided to further examine options for restriction of sales.

The Board discussed the ongoing need for statutory exceptions for GBL from schedule I based upon legitimate industrial or other use. Cynthia Benning indicated that language had been prepared and submitted to this end during the last session of the legislature, but the legislation it was attached to had failed to pass. William Black also indicated that the department had a procedure to assist in requesting legislation that might also be utilized.

MOTION: Robert Sloey moved, seconded by Thomas Rudy, for Cynthia Benning to continue to work with the legislature for introduction of legislation for statutory exceptions for GBL from schedule I based upon legitimate industrial or other use. Motion carried unanimously.

SCAODA REPORT OPTIONS

Roma Rowlands discussed the treatment options that Ira Hutchinson, Administrator of the DEA, addressed for offenders at the seminar she attended.

INFORMATIONAL ITEMS

Roma Rowland discussed the use of SOMA. Roma is looking for a trend on brand drugs versus generic drugs on Medicaid data. She is looking at pharmacies and the number of customers each pharmacy has and then comparing the data.

ADJOURNMENT

MOTION: Thomas Rudy moved, seconded by Roma Rowlands, that the meeting be adjourned. Motion carried unanimously.

The meeting adjourned at 10:50 a.m.

The next meeting is scheduled for December 4th, 2002.